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Summary 
CTLA-4, a CD28 homologue expressed on activated T  cells, binds with high affinity to the 
CD28 ligands,  B7-1 (CD80) and B7-2 (CD86). This study was designed to examine the role of 
CTLA-4 in regulating autoimmune disease.  Murine relapsing-remitting experimental autoim- 
mune encephalomyelitis (R-EAE) is a demyelinating disease mediated by PLP139-151-specific 
CD4 + T  cells in sJL/J mice. Anti-CTLA-4 mAbs (or their F(ab) fragments) enhanced in vitro 
proliferation and pro-inflammatory cytokine production by PLP139-151-primed lymph node 
cells. Addition of either reagent to in vitro activation cultures potentiated the ability of T  cells 
to adoptively transfer disease  to naive recipients. In vivo administration of anti-CTLA-4 mAb 
to recipients of PLP139-151-specific T  cells resulted in accelerated and exacerbated disease.  Fi- 
nally, anti-CTLA-4 treatment of mice during disease remission resulted in the exacerbation of 
relapses.  Collectively, these results suggest that CTLA-4 mediates the downregulation of ongo- 
ing immune responses and plays a major role in regulating autoimmunity. 
T 
cell activation requires the delivery of at least two sig- 
nals  to  the  T  cell  by  the  antigen-presenting  cell 
(APC). One signal is antigen-specific and is provided by the 
ligation  of the  T  cell  receptor  (TClq.)  by antigen-MHC 
complexes, whereas the second "costimulatory" signal may 
be provided by the B7 family of molecules, B7-1  (CD80) 
or B7-2  (CD86),  expressed on the APC.  Interactions be- 
tween CD28  on the T  cell and the B7  molecules on the 
APC are critical, both in vivo and in vitro, in preventing T 
cell  unresponsiveness  (1-4).  The  discovery of the  CD28 
homologue, cytotoxic T lymphocyte associated molecule~4 
(CTLA-4), by subtractive mRNA  cloning of cytotoxic T 
cells  (5) has increased the complexity of costimulatory inter- 
actions. CTLA-4 binds with higher affinity to the B7-1 and 
B7-2  molecules  (6).  CTLA-4Ig,  a  soluble  recombinant 
form of CTLA-4, is a potent inhibitor of B7/CD28 inter- 
actions and inhibits in vivo antigen-specific responses (2, 3, 
7,  8).  However,  the  regulatory  function  of the  native 
CTLA-4 molecule on the T  cell surface has only recently 
been appreciated. 
The cytoplasmic tail of human  and murine  CTLA-4 is 
highly  conserved (9),  suggesting that  it  is  involved in  an 
important signaling function. Surface expression of CTLA-4 
seems to be a tightly regulated event with transient expres- 
sion on activated T  cells,  peaking at 48-72 h  after activa- 
tion  (10,  11).  Initial  studies  suggested  that  anti-CTLA-4 
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antibodies could synergize with anti-CD3  and anti-CD28 
to enhance T  cell proliferation (10,  12).  Thus, it was con- 
cluded that CTLA-4 was an additional costimulatory mole- 
cule that had functions cooperative with those  of CD28. 
However, recent studies have indicated that CTLA-4 may, 
in fact, serve as a negative regulator ofT cell activation. We 
have shown that soluble anti-CTLA-4 mAb  as well as its 
F(ab)  fragments  increased  T  cell  proliferation in  murine 
ML1L responses (11). Additionally, intact cross-linked anti- 
CTLA-4 mAb,  but not its  F(ab)  fragments, could inhibit 
proliferation in T  cells stimulated with anti-CD3 and anti- 
CD28 (11,  13). Thus, it is likely that CTLA-4 functions to 
downregulate T  cell responses such that blockade of CTLA- 
4/B7 interaction results in enhanced T cell activation. Other 
studies also support a negative regulatory role for CTLA-4. 
Cross-linking  of CTLA-4  after the  ligation  of CD3  and 
CD28 strongly inhibited proliferation and IL-2 production 
(14).  In  vivo  treatment  of mice  with  anti-CTLA-4  was 
shown  to enhance  clonal expansion of antigen-specific T 
cells after immunization (15)  and enhance anti-tumor im- 
munity  (16).  In  fact,  CTLA-4  knockout  mice  express  a 
lymphoproliferative disorder  resulting  in  massive  infiltra- 
tion of several organs leading to early death (17,  18).  To- 
gether, these studies support an essential  role for CTLA-4 
in the downregulation of potentially autoaggressive T  cells. 
The present study was conducted to directly examine the 
role of CTLA-4 in regulating autoantigen-specific responses 
in autoimmune  disease.  Relapsing-remitting experimental 
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lished nmrine model for multiple sclerosis (MS)  character- 
ized by CD4 + T  cell-mediated demyelination in the cen- 
tral nervous system (CNS)  (19). R-EAE is induced in SJL/J 
mice by immunization with the immunodominant epitope 
on  proteolipid protein  (PLP139-151)  or  by  the  adoptive 
transfer  of PLP139-151-specific  T  cells  (20).  The  clinical 
disease is characterized by an acute paralytic phase followed 
by recovery and  subsequent  relapses accompanied by de- 
velopment of T  cell responses to  endogenous  epitopes on 
myelin proteins (e.g., PLP178-191),  a phenomenon termed 
epitope spreading (21, 22).  CD28/B7-mediated costimula- 
tory interactions play a major role in the establishment and 
progression of P,-EAE. Treatment of mice with CTLA-4Ig 
has been shown to inhibit disease induction (8). Anti-B7-1 
or anti-B7-2 treatments have differential effects on autoim- 
mune diseases including R-EAE (23, 24)  and autoimmune 
diabetes (25).  Together,  these studies emphasize the com- 
plexity of costimulatory interactions between B7 molecules 
and CD28  or CTLA-4.  In this study, we have directly ad- 
dressed the role of CTLA-4 in modulating PLP 139-15 l-spe- 
cific T  cell responses and in regulating disease using an anti- 
CTLA-4 mAb, known to prevent CTLA-4/B7 interactions. 
Both  intact Ig and F(ab) fragments had similar effects in all 
the  responses  studied,  suggesting that  these  reagents  were 
blocking  CTLA-4-mediated  events.  First,  anti-CTLA-4 
mAb  enhanced  in  vitro  proliferation  and  production  of 
pro-inflammatory cytokines by PLP139-151-primed lymph 
node ceils. Second, addition ofanti-CTLA-4 to in vitro ac- 
tivation cultures resulted in potentiation of the ability of these 
cells to adoptively transfer R-EAE to naive recipients. Third, 
in vivo blockade of CTLA-4 in recipient mice, after adop- 
tive transfer of primed cells, also resulted in exacerbation of 
disease.  Finally, treatment  of mice  during  remission, after 
the acute phase of R.-EAE resulted in greater incidence and 
severity of relapses. These results indicate that CTLA-4 has 
an important role in the downregulation ofT cell responses 
in  autoimmune  disease  and  may  be  a  major  regulatory 
player in the control of ongoing immunopathology. 
Materials and Methods 
Mice.  Female SJL/J  mice, 6-7 wk old, were purchased from 
Harlan Laboratories (Indianapolis, IN), housed in the Northwest- 
ern animal care facility, and maintained on standard laboratory food 
and water ad libitum. Paralyzed mice were afforded easier access 
to food and water. 
Peptides.  PLP139-151  (HSLGKWLGHPDKF) was purchased 
from Peptides International (Louisville, KY). Amino acid compo- 
sition was verified by mass spectrometry and purity (>98%) was 
assessed by HPLC. 
In  Vitro Proliferation and Cytokine Assays.  Mice  were  immu- 
nized subcutaneously with 100 ~1 of a Complete Freund's Adju- 
vant (CFA) emulsion containing 200 ~,g of Mycobacterium tubercu- 
losis  H37Ra  (Difco  Labs.  Inc.  Detroit,  MI)  and  25  btg  of 
PLP139-151  distributed over three spots on the flank. On  day 
10, draining lymph node cells were harvested and cultured in 96- 
well microtiter plates at a density of 5  ￿  105 cells/well in a total 
volume of 200  ~xl Dulbecco's Modified Eagle Medium  (DME) 
containing 7%  fetal bovine  serum,  1 mM  glutamine,  1%  Pen- 
Strep,  1 mM nonessential amino acids and 5  X  10 -5 M  2-mer- 
captoethanol (complete DME-7; all products from Sigma Chem. 
Co., St. Louis, MO). Cells were allowed to incubate at 37~  for 
60 min with the indicated antibodies (10 ~g/ml) before the indi- 
cated doses of antigen were added. Cultures were pulsed with 1 IxCi 
of [3H]TdR after 72  h,  harvested at 96  h  and  [3H]TdR uptake 
determined by scintillation counts. Results are expressed as mean 
of triplicate cultures -+ SEM (background counts subtracted). Su- 
pernatants collected at 24  and 48  hours  from  replicate cultures 
were assayed for IL-2, IL-4, and IFN-y levels using ELISA Mini- 
Kits (Endogen, Cambridge, MA). Minimal detection limits of the 
assays were "~  pg/ml for IL-2 and IL-4 and 30 pg/nfl for IFN-% 
Flow Cytometry.  FACS  |  analysis  was  performed  using  the 
FACScan  |  flow cytometer as described previously (11,  24).  PE- 
conjugated anti-CD3 and FITC-conjugated control Ig were pur- 
chased from PharMingen (La Jolla, CA). 
Induction  of  R-EAE  by  Active Immunization  with  PLP139- 
151.  Mice were immunized with 80 txg PLP139-151  in CFA 
as previously described (20). 
Adoptive Transfer qfR-EAE.  Donor  mice  were  immunized 
with 25  ~g of PLP139-151  in CFA. Draining lymph node cells 
were harvested on day t0 and cultured in either T25  (total vol- 
ume:  15  ml) or T75  (30  ml) flasks at 8  ￿  1()  ~' cells/ml with 20 
#,g/ml  of PLP139-151.  In  antibody-containing cultures,  cells 
were incubated at 37~  for 60 rain with the indicated mAbs (11) 
L~g/ml) before  the  addition  of antigen.  On  day  4,  cells  were 
washed in PBS, counted, and transferred i.p. into naive recipients 
in a total volume of 0.5 ml PBS.  Recipient mice received a sub- 
optimal dose of 6-7 ￿  106 live cells each. 
Antibody  Treatments.  The  following mAbs  were  employed: 
hamster control lg (Cappel Research Products, Cochranville, PA) 
and the anti-CTLA-4 mAb (UCll-4F10)  (11).  Antibodies and 
F(ab)  fragments  were  produced  and  purified as  previously de- 
scribed (11,  25).  Mice were treated, as indicated, either starting 
on the day of adoptive transfer or after recovery from the initial 
paralytic episode of R-EAE  (~25  d post-immunization). 50  txg 
of antibody was  administered i.p. every other day for five treat- 
ments (250  txg total) and mice were monitored for clinical signs 
of disease for an additional 20-40 d. 
Clinical Evaluation.  Clinical severity was assessed on a 0 to 5 
scale  as  described (24).  The  data are plotted as the  daily mean 
clinical score for all animals in a particular treatment group. A re- 
lapse was defined as a sustained increase of at least one full grade 
in clinical score after the animal had previously improved at least 
a full clinical score and had stabilized. Mean maximal severity is 
the mean of the highest clinical score reached by mice within an 
experimental group which displayed clinical signs. 
Statistical Analyses.  Comparison of the percentage of animals 
showing clinical disease and/or relapses between any two groups 
of mice  were  analyzed by  X  2 using  Fisher's exact probability. 
Comparisons of the  mean  day of onset of disease/relapse, and 
mean peak disease severity between any two groups of mice were 
analyzed by the Student's t test. P values <0.05 were considered 
significant. 
Results and Discussion 
Anti-CTLA-4 mAb Enhances  PLP139-151-Specific In  Vitro 
Proliferative and Cytokine Responses.  Recent  in  vitro  stud- 
ies have  employed allogeneic MLR  or anti-CD3  stimula- 
tion to assess the expression and function of CTLA-4 on T 
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Anti-CTLA-4 mAb enhances in vitro proliferation and cy-  Figure  1. 
tokine production by PLP139-151-primed  lymph node cells. (A) Drain- 
ing lymph node cells from PLP139-151/CFA-primed  mice were cultured 
with 0.5 btM PLP139-151 and 10 b~g/ml  of control or anti-CTLA-4 anti- 
bodies. Data represents the mean thymidine uptake of triplicate cultures 
and is plotted as A counts per minute + SEM (background  counts [1712 + 
138] subtracted). These results are representative of six separate experi- 
ments. (B and C) Supernatants  from replicate experiments  were collected 
after 24 h of culture and assayed for 1L-2 and IFN-7 levels by ELISA. 
Data is plotted as mean cytokine levels  in pg/ml + SD at a peptide dose 
of 0.5 I-tM (IL-2) or 15 la,  M (IFN-~/). Results are representative  of three 
separate experiments. 
cells (10, 11, 14). To address the functional role of CTLA-4 
in nominal antigen-specific immune responses, mice were 
immunized with  the  immunodominant PLP139-151  epi- 
tope and the effects of anti-CTLA-4 mAb (10  Ixg/ml) on 
in vitro proliferation and cytokine production by primed 
lymph node cells were determined. As seen in Fig. 1 A, the 
anti-CTLA-4  mAb  significantly  enhanced  PLP139-151- 
specific proliferation. Higher concentrations of antibodies 
enhanced  proliferative  responses  even  further  (data  not 
shown). 24-h supematants from replicate cultures were as- 
sayed for  IL-2,  IL-4,  and  IFN-"v levels by ELISA.  Anti- 
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Figure 2.  Addition  ofanti-CTLA-4 ]nAb to in vitro activation  cultures 
enhances the ability to transfer R-EAE. Control or anti-CTLA-4 anti- 
bodies were added to in vitro activation cultures of PLP139-151-primed 
cells. On day 4, 6 X 106 total live cells  were transferred i.p. into naive re- 
cipients. Mice were then graded for clinical  signs of R-EAE. Data is plot- 
ted as mean  clinical  score vs. days post-transfer. Disease incidences  in the 
different groups were 4/7(Control), 6/6 (anti-CTLA-4) and 5/6  (anti- 
CTLA-4 F(ab)). Mean days of onset were 17.8, 12.5", and 14.2" d respec- 
tively (*P <0.05). Figures in parentheses indicate mean maximal clinical 
severity in each group (*P <0.05). Results are representative  of four sepa- 
rate experiments. 
CTLA-4 mAb resulted in significantly enhanced IL-2 and 
IFN-y production (Fig. 1, B and C). No IL-4 was detected 
in any of the  supernatants (data  not shown).  Similar pat- 
terns  of enhanced proliferation and  cytokine  production 
were seen with varying peptide doses and after varying cul- 
ture times. The F(ab) fragments and the intact anti-CTLA-4 
antibody had  the  same  enhancing effect,  consistent with 
previous studies (11,  15), suggesting that the enhancement 
of proliferation and  cytokine production was  due  to  the 
blockade of CTLA-4-mediated downregulatory events. 
Addition of Anti-CTLA-4  mAb to In  Vitro Activation  Cul- 
tures Enhances  the  Ability  of PLP139-151-specific  T  Cells  to 
Transfer R-EAE to Naive Recipients.  We next tested whether 
blockade of CTLA-4/B7 ligation altered the generation of 
encephalitogenic PLP139-151-specific cells.  PLP139-151- 
primed  lymph  node  cells  were  activated  in  vitro  in  the 
presence  of control  lg  or  anti-CTLA-4 antibodies.  En- 
cephalitogenicity of the resulting cells was then assessed  by 
the expression of clinical disease after the adoptive transfer 
of a suboptimal dose of 6  ￿  106 viable cells to naive recipi- 
ents.  Cells cultured with  either anti-CTLA-4 or its  F(ab) 
fragments were  significantly more  efficient at  transferring 
R-EAE (Fig. 2). Mice receiving anti-CTLA-4-treated cells 
demonstrated an  accelerated  disease  course  (mean  day  of 
onset:  12.5"  d  and  14.2"  d  in antibody-treated groups vs. 
17.8 d in controls; *P <0.05)  and a higher mean maximal 
disease severity (2.3 mean peak score in controls vs. 2.8 in 
the  anti-CTLA-4-treated group  and  3.4"  in  the  F(ab)- 
treated  group;  *P  <0.05).  These  results indicate that  the 
blockade of CTLA-4/B7 interactions in the activation cul- 
tures  resulted  in  an  enhanced encephalitogenicity of the 
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mAb  treatment  also  resulted in  elevated proliferation and 
cytokine production by PLP139-151-specific T  cells (Fig. 1), 
the enhanced disease course may be due to the transfer of a 
higher number  of effector T  cells and/or  of effector cells 
capable of producing enhanced levels of pro-inflammatory 
cytokines. 
In  Vivo  Treatment  with  Anti-CTLA-4  mAb  Exacerbates 
Adoptive R-EAE.  We next examined whether  CTLA-4- 
mediated  events  downregulated  PLP139-151-specific  T 
cells in vivo. Activated PLP139-151-specific cells were adop- 
tively transferred to naive SjL/j recipients. Recipient mice 
were  then treated with control Ig, intact anti-CTLA-4, or 
anti-CTLA-4  F(ab)  fragments.  Anti-CTLA-4  mAb  treat- 
ment exacerbated clinical disease (Fig. 3). Disease onset was 
accelerated  (mean  day  of onset  (MDO):  7.0*  d  in  anti- 
CTLA-4  treated  group  vs.  13.0  d  in  controls;  *P  <0.01) 
and  the  mean  maximal  severity  of  the  anti-CTLA-4- 
treated groups was significantly greater (3.0  in controls vs. 
4.6*  in  anti-CTLA-4-treated groups;  *P  <0.01).  In  vivo 
treatment with anti-CTLA-4 F(ab) fragments similarly ac- 
celerated and exacerbated disease with a MDO  of 10.0"  d 
and  a  mean  maximal severity of 3.7*;  *P <0.05  (data not 
shown). Thus, it appears that CTLA-4-mediated events play 
a  role in  the  downregulation  of the  autoimmune  effector 
functions  and/or  the  in  vivo expansion  of the  adoptively 
transferred cells. Flow cytometric analyses of PLP139-151- 
primed lymph node  cells activated in culture showed  up- 
regulation of surface  CTLA-4  expression on  T  cells  (data 
not shown).  Lymph node cells taken ex vivo from primed 
mice  showed  little CTLA-4  expression  (time  0  h)  which 
peaked after in vitro activation at about 72 h  of culture, as 
described before in other systems (11). At the time of adop- 
tive  transfer  (96  h),  a  small,  but  significant  population 
("~  of T  cells,  showed  surface  CTLA-4  expression. 
Treatment  of the  recipient animals starting on  the  day of 
transfer could result in the enhancement of pro-inflamma- 
tory  phenomena  due  to  blockade  of CTLA-4-mediated 
downregulatory events in this population of effector cells, 
or  on  other T  cells within  the  transfer population which 
may upregulate CTLA-4 after presentation of self peptides 
in the CNS. 
Anti-CTLA-4  mAb  Treatment  Exacerbates  Relapses  in 
R-EAE.  R-EAE induced by immunization with PLP139- 
151  exhibits a  relapsing and remitting disease course.  The 
acute phase of disease is due to the activity ofCD4 + T  cells 
specific for  the  PLP139-151  epitope.  However,  we  have 
recently shown (21) that the primary disease relapse is prin- 
cipally due to the activity of T  cells specific for an endoge- 
nous,  non-cross-reactive  epitope  on  PLP  (PLP178-191) 
which  are  activated  as  a  result  of recognition  of myelin 
epitopes released during acute disease, a phenomenon known 
as  epitope spreading.  Tolerization of PLP178-191-specific 
T  cells (unpublished observations) or inhibition of PLP178- 
191-specific  responses  by  the  blockade of BT-l-mediated 
costimulatory signals during disease remission blocks disease 
relapses (24).  To  assess  the  role  of CTLA-4 in  disease re- 
lapses,  mice  were  treated with  anti-CTLA-4 mAb during 
remission,  i.e.,  after  they  had  recovered  from  the  acute 
phase of active disease. Anti-CTLA-4 treatment resulted in 
an increased disease severity and a  higher incidence of re- 
lapses (Fig. 4).  Four out  of the  seven mice in the  control 
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Figure  3.  In vivo CTLA-4 blockade exacerbates adoptive R-EAE. 
1<-EAE was initiated by adoptive transfer of PLP 139-151 -specific T cells. 
Starting on the day of transfer, mice were treated i.p. with either control 
or anti-CTLA-4 mAbs  and graded for clinical signs of EAE. Data is plot- 
ted as the mean clinical score vs. days post-transfer. Disease incidences 
were 8/8 (control group) and 8/8  (anti-CTLA-4-treated group). Mean 
days of onset were  13.0 and 7.0* d, respectively (*P <0.01).  Figures in 
parentheses indicate mean peak clinical severity in each group (*P <0.01). 
Results are representative of three separate experiments. 
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Figure  4.  Anti-CTLA-4 treatment  exacerbates  disease relapses in 
R-EAE.  Active R-EAE  was  induced  by priming  with  PLP139-151/ 
CFA. After recovery from the acute phase of disease ('-~  d post immu- 
nization), mice were treated with either control Ig or intact anti-CTLA-4 
mAb. Data is plotted as the relapse rate (total nmnber  of relapses in a 
group divided by the total number of mice in that group) vs. days post- 
treatment  initiation.  4/7  mice  in  the  control  group  showed  relapses, 
whereas 6/6 mice in the anti-CTLA-4-treated group relapsed (two mice 
relapsed two times each making a total of 8 relapses  in 6 mice). Figures in 
parentheses indicate the mean peak clinical score of the relapses. These re- 
suits are representative of two separate experiments. *Number of relapses 
are significantly  greater than that of the hamster Ig controls, P <0.05. 
786  Anti-CTLA-4 mAb Treatment Exacerbates  Murine EAE group showed relapses  whereas  six out of six mice in the 
anti-CTLA-4 treated group relapsed, with two mice show- 
ing two relapses each (P <0.05). 
Collectively, the data presented in this paper support the 
hypothesis  that  CTLA-4  is  a  major  negative  regulator  of 
autoimmune T  cell function both in vitro and in vivo and 
emphasizes  the  complicated nature  of costimulatory inter- 
actions. We have shown that the blockade of CTLA-4 in- 
teractions  with  its  ligands  resulted  in the  enhancement  of 
every  effector  function  studied,  including  proliferation, 
pro-inflammatory  cytokine  production,  encephalitogenic- 
ity,  and  the  ability  to maintain  ongoing autoimmune  dis- 
ease.  These results are consistent with a model of costimu- 
latory interactions,  where  initial  activation of T  cells  after 
antigen exposure is mediated by CD28/B7 interactions and 
leads  to  the  proliferation  and  differentiation  of effector T 
cells.  Activated  T  cells  express  CTLA-4  on  their  surface, 
which can bind the same B7-family ligands with higher af- 
finity  and  result  in  the  downregulation  of the  T  cell  re- 
sponse. The net T  cell response would then be a result of a 
balance between CD28 and CTLA-4-mediated events. 
Our recent results show that, during the course of R-EAE, 
there  is preferential  upregulation  of B7-1,  as  compared to 
B7-2, both in the CNS and in the splenic lymphoid com- 
partment (24).  Such dynamic changes in costimulatory ligand 
expression during a chronic inflammatory autoimmune re- 
sponse may reflect an attempt at downregulating a destruc- 
tive response. Based on the parallel late upregulation of B7-1 
and CTLA-4, it has been suggested that B7-1  may be the 
preferred  ligand  for  CTLA-4  (26).  Our  preliminary  data 
suggest that there are dramatic differences in B7 ligand ex- 
pression depending on the lymphoid tissue examined.  It is 
tempting to speculate that certain compartments of the im- 
mune  system  may be  involved  in  providing  an  environ- 
ment  which  promotes  pro-inflammatory  events,  whereas 
other  compartments  may be  primarily  responsible  for the 
ultimate  downregulation  of T  cell responses.  Our current 
studies are directed towards addressing these issues by care- 
fully following the  expression  and  functions  of B7  mole- 
cules  and their  T  cell ligands  in animals with  an  apparent 
self regulating autoimmune disease such as observed during 
relapsing-remitting EAE. 
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